Tech Transfer eNews Blog

Exagen licenses novel fibromyalgia blood test from Ohio State U


By Jesse Schwartz
Published: June 24th, 2020

Exagen Diagnostics, an organization focused on improving care for patients with autoimmune diseases, has signed an exclusive worldwide license agreement for a novel blood test to detect fibromyalgia from the Ohio State Innovation Foundation.

Fibromyalgia is the leading cause of chronic musculoskeletal pain in the U.S., especially among women. However, there may be as many as 12 million patients who have gone undiagnosed because the symptoms are similar to those of other pain-related disorders.

Developed by researchers at Ohio State University (OSU), the blood test licensed by Exagen uses vibrational spectroscopy and metabolomic analysis to differentiate patients with fibromyalgia from rheumatoid arthritis, chronic lower back pain, and other similar disorders.

“Approximately thirty percent of fibromyalgia patients may test positive for anti-nuclear antibodies, raising autoimmune disease concerns and resulting in potentially inappropriate referrals to rheumatologists,” says Ron Rocca, president and CEO of Exagen.

“In addition, patients with fibromyalgia and autoimmune diseases such as lupus and rheumatoid arthritis may have similar symptoms especially in early stage disease, making differential diagnosis difficult,” Rocca continues. “A rule-in test for fibromyalgia would be a significant advancement in the earlier diagnosis and appropriate treatment of these patients.”

Scott Osborne, vice president of economic and corporate engagement at OSU, comments, “Fibromyalgia is often difficult to diagnose. This research providing evidence that fibromyalgia can be detected in blood samples exemplifies Ohio State’s mission to improve lives by finding solutions to complex problems.”

Source: BioSpace

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment